Italia markets closed

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,4000+0,0650 (+2,78%)
Alla chiusura: 04:00PM EDT
2,3500 -0,05 (-2,08%)
Dopo ore: 07:30PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,3350
Aperto2,3100
Denaro2,3900 x 1000
Lettera2,4200 x 700
Min-Max giorno2,2800 - 2,4798
Intervallo di 52 settimane2,2800 - 9,0800
Volume2.316.184
Media Volume1.644.039
Capitalizzazione348,221M
Beta (5 anni mensile)1,24
Rapporto PE (ttm)N/D
EPS (ttm)-1,5600
Prossima data utili07 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A6,40
  • GlobeNewswire

    Adaptive Announces Launch of Epic Integration for clonoSEQ®

    The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancersSEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ® is now available to health care providers as a fully integrated

  • GlobeNewswire

    Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

    SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York Adaptive Biotechnologies’ management is scheduled to participate in a fireside

  • GlobeNewswire

    Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results

    SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2023. “We had another strong quarter with clonoSEQ test volume growth of 52% versus prior year and the first FDA IND acceptance in cancer cell therapy